Tag
TBX2 is identified as a key transcription factor repressing vascular calcification by controlling RUNX2 and the inflammatory NLRP3 pathway, highlighting new therapeutic targets to reduce cardiovascular risk in CKD.
This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival
In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in athero
The NLRP3 inflammasome plays a central role in inflammation-mediated sensorineural hearing loss (SNHL). Genetic and acquired activation causes cochlear damage through cytokine release and pyroptosis. Targeted therapies, including IL-1 block
This article explores how gut microbiota dysbiosis and NLRP3 inflammasome activation contribute to secondary white matter injury post-intracerebral hemorrhage, outlining mechanisms and potential therapeutic strategies.
